Home Newsfeeds Raymond James Downgrades Saul Centers to Market Perform

Raymond James Downgrades Saul Centers to Market Perform

Raymond James analyst RJ Milligan downgrades Saul Centers (NYSE:BFS) from Outperform to Market Perform.

byBenzinga Newsdesk

January 4, 2023

1 minute read

Raymond James analyst RJ Milligan downgrades Saul Centers (NYSE:BFS) from Outperform to Market Perform.

Ford Slows Down Electric SUV Production Amid Demand Concerns

By Shivani Kumaresan

April 4, 10:56 AM

Ford delays launch of new electric vehicles to 2027. Decision driven by market expansion and battery tech advancements.

Barclays Says ‘The Worst Is Yet To Come’ For Beyond Meat And Tyson Foods As Inflation Takes A Bite Out Of Profits

By Adam Eckert

November 28, 1:44 PM

Barclays analysts expect protein sales to be impacted by rising prices for years to come, hence the downgrade of Beyond Meat Inc (NASDAQ: BYND) and Tyson Foods, Inc. (NYSE: TSN) Monday morning.

BYND

Freshpet Advances Operational Improvement Plan With New Talent Addition; Reiterates FY22 Guidance For Net Sales And Adjusted EBITDA

By Benzinga Newsdesk

January 9, 9:32 AM

Ennis Kitchen On-track and Shipping a Wide Range of SKU's Reiterates Full Year 2022 Guidance for Net Sales and Adjusted EBITDA SECAUCUS, N.J., Jan. 09, 2023 (GLOBE NEWSWIRE) -- Freshpet, Inc.

FRPT

Nurix Therapeutics Presents Clinical Data From Its Novel Bruton’s Tyrosine Kinase Degrader Programs, NX-5948 And NX-2127, At The 65th American Society Of Hematology Annual Meeting

By Benzinga Newsdesk

December 11, 1:02 PM

Positive preliminary efficacy data with a favorable safety profile support plans to develop NX-5948 broadly in chronic lymphocytic leukemia (CLL)Rapid durable complete responses in a heavily pretreated

NRIX

Raymond James Downgrades Saul Centers to Market Perform

Related Posts

Ford Slows Down Electric SUV Production Amid Demand Concerns

Barclays Says ‘The Worst Is Yet To Come’ For Beyond Meat And Tyson Foods As Inflation Takes A Bite Out Of Profits

Freshpet Advances Operational Improvement Plan With New Talent Addition; Reiterates FY22 Guidance For Net Sales And Adjusted EBITDA

Nurix Therapeutics Presents Clinical Data From Its Novel Bruton’s Tyrosine Kinase Degrader Programs, NX-5948 And NX-2127, At The 65th American Society Of Hematology Annual Meeting